Skip to main content
. Author manuscript; available in PMC: 2017 Jul 11.
Published in final edited form as: Adv Pharmacol. 2014 Aug 22;71:203–243. doi: 10.1016/bs.apha.2014.06.002

Figure 13.

Figure 13

Effect of intetumumab and bevacizumab on brain tumor vasculature. Rats with intracerebral LX-1 SCLC xenografts were randomized to no treatment, intetumumab anti-αv integrin mAb, or bevacizumab anti-VEGF mAb. Rats underwent serial dynamic contrast-enhanced MRI with gadolinium-based contrast agent to evaluate vascular permeability (A) and dynamic susceptibility-weighted contrast-enhanced MRI with ferumoxytol to evaluate relative cerebral blood volume (rCBV) (B). Bevacizumab decreased vascular permeability and rCBV within 24 h, while intetumumab increased both permeability and rCBV over a week following treatment. Reprinted from Muldoon, Gahramanov, et al. (2011) by the permission of Society for Neuro-Oncology.